Nls Pharmaceutics LTD Form 4 insider transactions

Samuel Olivier, a Director at NewcelX Ltd., reported transactions involving the acquisition of common shares and warrants on April 27, 2026.

NLS Pharmaceutics and Kadimastem announced a Hong Kong patent grant for their IsletRx cell-selection technology, expanding global intellectual property protection for their diabetes therapy candidate.

NLS Pharmaceutics Ltd. and Kadimastem Ltd. have extended their merger agreement termination date to October 31, 2025, to address further SEC comments on their Form F-4 registration statement.

NLS Pharmaceutics Ltd. and Kadimastem Ltd. have signed a sixth amendment to their merger agreement, clarifying the timing for calculating the exchange ratio based on pre-shareholder meeting data.

NLS Pharmaceutics Ltd. and Kadimastem Ltd. have agreed to a fifth amendment to their merger agreement, extending the termination date from June 30, 2025, to August 31, 2025, to facilitate the completion of the transaction.

NLS Pharmaceutics' CEO provides a comprehensive update on recent financing, positive clinical developments, and the anticipated merger with Kadimastem, targeting early Q3 2025 completion.

NLS Pharmaceutics Ltd. and Kadimastem Ltd. have signed a fourth amendment to their merger agreement, clarifying the post-closing share split, cash requirements, and board election conditions to facilitate the transaction's completion.

NLS Pharmaceutics reports positive preclinical results from Study KO-943, demonstrating that Mazindol reduces fentanyl-induced reward in animal models, suggesting its potential as a non-opioid treatment for fentanyl use disorder.

NLS Pharmaceutics announces a $3 million equity financing and a $25 million committed equity facility to support its merger with Kadimastem and advance clinical trials.

NLS Pharmaceutics provides an update on its strategic merger with Kadimastem, progress in diabetes and neurodegenerative disease treatments, and financial stability.

Kadimastem and iTolerance successfully completed a pre-IND meeting with the FDA regarding their collaborative development of iTOL-102, a potential cure for Type 1 Diabetes.

NLS Pharmaceutics and Kadimastem are merging to create a holistic solution for diabetes management, focusing on a multi-target approach that goes beyond traditional GLP-1 therapies.

Kadimastem shareholders have approved the merger with NLS Pharmaceutics, marking a significant step towards creating a combined entity focused on neurodegenerative diseases and diabetes.

NLS Pharmaceutics has announced the launch of a preclinical program to evaluate Mazindol ER as a potential non-opioid treatment for fentanyl dependence, addressing a critical global health crisis.

Kadimastem has announced a special general meeting of shareholders to vote on the proposed merger with NLS Pharmaceutics, marking a significant step towards the completion of the transaction.

NLS Pharmaceutics and Kadimastem have successfully completed the initial closing of a $500,000 fundraising round, part of a previously announced $1 million financing, at a share price 48% above the market price.

NLS Pharmaceutics and Kadimastem have filed a registration statement with the SEC for their proposed merger, aiming to create a Nasdaq-listed biotech company.

NLS Pharmaceutics and Kadimastem, in collaboration with iTolerance, have submitted a request for a Pre-Investigational New Drug (Pre-IND) meeting with the FDA for their innovative Type 1 Diabetes treatment, iTOL102.

NLS Pharmaceutics CEO provides an update to shareholders regarding the company's progress on its DOXA program, financial restructuring, and the upcoming merger with Kadimastem Ltd.

NLS Pharmaceutics will merge with Kadimastem, with Kadimastem shareholders expected to own 80% of the combined company on a fully diluted basis.

NLS Pharmaceutics and Kadimastem have entered into a definitive merger agreement to combine their operations, focusing on NLS's Dual Orexin Agonist (DOXA) platform and Kadimastem's allogeneic cell therapy program.